Clinical Trial Update: A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating JAB-21822 as monotherapy for pancreatic cancer and other KRAS G12C-mutant solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• JAB-21822

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: KRAS P.G12C, Pancreatic Cancer | Phase 2 | Status: RECRUITING